In an exciting development, Radicava, also known as edaravone, is the first drug approved by the FDA to treat amyotrophic lateral sclerosis (ALS) in 22 years. This drug is a pricey one at $145,000 a year for treatment, but for the approximately 15,000 sufferers of ALS it will be worth it.
“At Week 24, individuals receiving edaravone declined less on a clinical assessment of daily functioning compared to those receiving a placebo. ”
ALS is a very difficult disease to treat, with only one other approved medication to ease the progression. Even with treatment it is always fatal, but nevertheless a new treatment is still an important development for thousands of sufferers. The drug may also have other uses for treating cognitive issues but it is still to early to tell if it has other applications.
The following two tabs change content below.